Lorlatinib is an Orally Active and Dual ALK/ROS1 Inhibitor
Oncogenic c-Ros oncogene1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy. The MET/ALK/ROS1 inhibitor has demonstrated promising clinical activity…